Kimmig W
Universitäts-Hautklinik und Poliklinik Hamburg.
Z Hautkr. 1989 Apr 15;64(4):266-8, 271.
In spite of modern, highly effective antiviral drugs, the treatment of herpes simplex infections is still unsatisfactory. Especially recurrent infections as well as the protection of immunocompromised patients remain little solved therapeutical problems. Neither is the vaccination of herpes simplex promising; this has been shown in a multicenter study on a new herpes simplex virus envelope antigen vaccine. Future genotechnical investigations might provide new vaccines, which might become significant for a prophylactic therapy of herpes simplex.
尽管有现代高效的抗病毒药物，但单纯疱疹感染的治疗仍不尽人意。特别是复发性感染以及免疫功能低下患者的保护问题，在治疗上仍未得到很好的解决。单纯疱疹疫苗也没有什么前景；这在一项关于新型单纯疱疹病毒包膜抗原疫苗的多中心研究中得到了证实。未来的基因技术研究可能会提供新的疫苗，这可能对单纯疱疹的预防性治疗具有重要意义。
